J
Jose A. Roca
Researcher at University of Buenos Aires
Publications - 34
Citations - 1486
Jose A. Roca is an academic researcher from University of Buenos Aires. The author has contributed to research in topics: Macular edema & Visual acuity. The author has an hindex of 18, co-authored 33 publications receiving 1347 citations. Previous affiliations of Jose A. Roca include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Lihteh Wu,Maria Ana Martinez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,Maria H. Berrocal,Michel Eid Farah,Mauricio Maia,Jose A. Roca,Francisco Rodríguez +8 more
TL;DR: Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.
Journal ArticleDOI
Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema: The Pan-American Collaborative Retina Study Group Results
J. Fernando Arevalo,Mauricio Maia,R. A. Garcia-Amaris,Jose A. Roca,Juan G. Sanchez,Maria H. Berrocal,Lihteh Wu +6 more
TL;DR: Short-term results suggest that IVT bevacizumab is well tolerated in patients with refractory pseudophakic CME and Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT at 12 months.
Journal ArticleDOI
Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Lihteh Wu,J. Fernando Arevalo,Jose A. Roca,Mauricio Maia,Maria H. Berrocal,Francisco Rodríguez,Teodoro Evans,Rogério A. Costa,José A. Cardillo +8 more
TL;DR: Intravitreal injection of bevacizumab at doses up to 2.5 mg appears to be effective in improving BCVA and reducing CMT in BRVO in the short term.
Journal ArticleDOI
intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
Lihteh Wu,Erick Hernandez-Bogantes,Jose A. Roca,J. Fernando Arevalo,Karen Barraza,Andres F. Lasave +5 more
TL;DR: Both intravitreal adalimumab and infliximab do not appear to benefit eyes with refractory diabetic macular edema and may elicit a severe intraocular inflammatory reaction.